Heart failure study aims to tailor treatments using biomarkers
NCT ID NCT07647848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 600 adults with chronic or acute heart failure to see how biomarkers and other factors predict individual responses to standard medications. Participants will have assessments at the start and after 1, 3, and 6 months, with follow-up phone calls every 6 months. The goal is to improve personalized treatment strategies for heart failure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors personalize heart failure treatments based on individual biomarkers, improving outcomes.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with either de novo HF or (acute) decompensated HF who are not yet on optimal doses of guideline-recommended therapies and in whom up-titration is anticipated. Patients will be enrolled either at the outpatient clinic of participating sites or prior to dis-charge of patients who are hospitalized for worsening HF
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Provide written and dated informed consent for participation prior to trial admission, 2. Age ≥18 years, female or male 3. A clinical diagnosis of new onset or worsening of heart failure with a left-ventricular ejection fraction of \<50% 4. On treatment with oral or i.v. furosemide ≥40 mg/day or equivalent (bumetanide 1mg, torasemide 10mg) 5. Receiving \<50% of the target doses of at least one of the guidelines recommended pharmacological therapies (clear intolerance not considered) 6. Anticipated or planned uptitration Exclusion Criteria: 1. Scheduled or on renal replacement therapy, 2. Clearly documented intolerance to two or more of the following groups of drugs: BB, ARNI, SGLT2i or MRAs. 3. Diagnosis of peripartum cardiomyopathy, chemotherapy induced cardiomyopathy, current viral myocarditis, right heart failure in absence of left-sided structural disease, pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy including amyloidosis. 4. The presence of a mechanical assist device, 5. Scheduled for mechanical assist device or heart transplant, 6. Current angina pectoris ≥class III, 7. Requiring valvular surgery or revascularization in the upcoming 3 months or Coronary Artery Bypass Grafting (CABG) within the past 3 months, 8. Anticipated need for surgery or any other cardiovascular intervention, except implantable cardioverter defibrillator and/or cardiac resynchronization therapy, within 4 weeks, 9. Other non-cardiac conditions with limited life expectancy (≤ duration of the trial/ 1 year), 10. Participation in another clinical trial apart from non-interventional studies. 11. Patients with an unscheduled hospital visit or admission for reasons that are not primarily related to worsening of heart failure. Therefore, patients with concomitant pulmonary disease, even if severe, valvular disease, acute coronary syndrome or stroke, may be included when the primary diagnosis for admission to hospital or outpatient clinic visit has been heart failure, rather than the concomitant condition. 12. Women who are pregnant, breastfeeding or those considering becoming pregnant 13. Subjects unable to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stick-On patch aims to catch dangerous heart decline sooner
- Can a traditional chinese medicine injection ease heart failure symptoms?
- A gentle electric pulse to the heart: new device tested for heart failure
- Can a heart drug shield the brain? a trial investigates Vericiguat's potential to slow cognitive decline
- Fine-Tuning heart failure drugs to flush out excess salt
- A supplement that could help heart failure patients shed excess fluid?